Abstract
Purpose
To evaluate the potential effects of background parenchymal enhancement of MR imaging in diagnosed breast cancer patients on the rate of additional biopsy and resultant cancer yield.
Materials and Methods
322 patients who were diagnosed with breast cancer and had undergone breast MR imaging were included in this study. Two radiologists reviewed the MRI for degree of background parenchymal enhancement and additional suspicious lesions described as BI-RADS category 4 or 5 on radiologic reports. Biopsy was done for these lesions, pathology reports were reviewed to calculate the cancer yield.
Results
Background parenchymal enhancement of MR imaging in a total of 322 patients were classified as minimal degree 47.5%, mild degree 28.9%, moderate degree 12.4% and marked degree 11.2%. Among these 332 patients, MR imaging of 70 patients showed additional suspicious malignant lesions described as BI-RADS category 4 or 5, and consequently, 66 patients underwent biopsy. Biopsy rates in those with minimal or mild background parenchymal enhancement and those with moderate and marked background parenchymal enhancement were 19.9% and 22.3% (p-value 0.77) respectively. Cancer yields in those with minimal or mild background parenchymal enhancement and those with moderate and marked background parenchymal enhancement were 6.5% and 5.2% (p value 0.88) respectively. Both these results did not show stastically significant difference between the two groups.
Figures and Tables
Table 1
Note.- 1)BPE-background parenchymal enhancement 1(minimal degree), 2(mild degree), 3(moderate degree), 4(marked degree)
2)C4A-BI-RADS category low suspicion of malignancy
3)C4B-BI-RADS category intermediate suspicion of malignancy
4)C4C-BI-RADS category moderate suspicion of malignancy
5)C5-BI-RADS category, highly suggestive of malignancy
References
1. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology. 1997; 203:137–144.
2. Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations. Radiology. 2005; 235:36–41.
3. DeMartini WB, Liu F, Peacock S, Eby PR, Gutierrez RL, Lehman CD. Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR Am J Roentgenol. 2012; 198:W373–W380.
4. Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA. Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR Am J Roentgenol. 2011; 196:218–224.
5. Morris EA. Diagnostic breast MR imaging: current status and future directions. Magn Reson Imaging Clin N Am. 2010; 18:57–74.
6. Uematsu T, Yuen S, Kasami M, Uchida Y. Comparison of magnetic resonance imaging, multidetector row computed tomography, ultrasonography, and mammography for tumor extension of breast cancer. Breast Cancer Res Treat. 2008; 112:461–474.
7. Uematsu T, Kasami M, Watanabe J. Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent. Breast Cancer. 2012; 19:259–265.
8. Kuhl C. The Current status of breast MR imaging Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology. 2007; 244:356–378.
9. Uematsu T, Kasami M, Watanabe J. Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer? Eur Radiol. 2011; 21:2261–2267.